Literature DB >> 32635180

Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design.

Dongliang Wang1, Jinhui Mai1, Wenfeng Zhou1, Wanting Yu1,2, Yang Zhan1, Naidong Wang1, Neal D Epstein3, Yi Yang1.   

Abstract

Currently, there is limited knowledge about the immunological profiles of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). We used computer-based immunoinformatic analysis and the newly resolved 3-dimensional (3D) structures of the SARS-CoV-2 S trimeric protein, together with analyses of the immunogenic profiles of SARS-CoV, to anticipate potential B-cell and T-cell epitopes of the SARS-CoV-2 S protein for vaccine design, particularly for peptide-driven vaccine design and serological diagnosis. Nine conserved linear B-cell epitopes and multiple discontinuous B-cell epitopes composed of 69 residues on the surface of the SARS-CoV-2 trimeric S protein were predicted to be highly antigenic. We found that the SARS-CoV-2 S protein has a different antigenic profile than that of the SARS-CoV S protein due to the variations in their primary and 3D structures. Importantly, SARS-CoV-2 may exploit an immune evasion mechanism through two point mutations in the critical and conserved linear neutralization epitope (overlap with fusion peptide) around a sparsely glycosylated area. These mutations lead to a significant decrease in the antigenicity of this epitope in the SARS-CoV-2 S protein. In addition, 62 T-cell epitopes in the SARS-CoV-2 S protein were predicted in our study. The structure-based immunoinformatic analysis for the SARS-CoV-2 S protein in this study may improve vaccine design, diagnosis, and immunotherapy against the pandemic of COVID-19.

Entities:  

Keywords:  B-cell and T-cell epitopes; S protein; SARS-CoV-2; vaccine

Year:  2020        PMID: 32635180     DOI: 10.3390/vaccines8030355

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  20 in total

1.  SARS-CoV-2 Epitopes following Infection and Vaccination Overlap Known Neutralizing Antibody Sites.

Authors:  Li Yang; Te Liang; Lane M Pierson; Hongye Wang; Jesse K Fletcher; Shu Wang; Duran Bao; Lili Zhang; Zhen Huang; Wenshu Zheng; Xiaomei Zhang; Heewon Park; Yuwen Li; James E Robinson; Amy K Feehan; Christopher J Lyon; Jing Cao; Lisa A Morici; Chenzhong Li; Chad J Roy; Xiaobo Yu; Tony Hu
Journal:  Research (Wash D C)       Date:  2022-07-09

2.  Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate.

Authors:  Ileanet Ávalos; Thailin Lao; Elsa María Rodríguez; Yasser Zamora; Alianet Rodríguez; Ailyn Ramón; Gilda Lemos; Ania Cabrales; Monica Bequet-Romero; Dionne Casillas; Ivan Andújar; Luis Ariel Espinosa; Luis Javier González; Yanitza Alvarez; Yamila Carpio; Mario Pablo Estrada
Journal:  Vaccines (Basel)       Date:  2022-06-03

3.  Abrogation of SARS-CoV-2 interaction with host (NRP1) neuropilin-1 receptor through high-affinity marine natural compounds to curtail the infectivity: A structural-dynamics data.

Authors:  Fahad Humayun; Abbas Khan; Sajjad Ahmad; Wang Yuchen; Guoshen Wei; N Nizam-Uddin; Zahid Hussain; Wajid Khan; Nasib Zaman; Muhammad Rizwan; Muhammad Waseem; Dong-Qing Wei
Journal:  Comput Biol Med       Date:  2021-07-31       Impact factor: 6.698

Review 4.  COVID-19 vaccine: where are we now and where should we go?

Authors:  Saman Soleimanpour; Atieh Yaghoubi
Journal:  Expert Rev Vaccines       Date:  2021-02-17       Impact factor: 5.217

5.  Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.

Authors:  Qiu-Dong Su; Ye-Ning Zou; Yao Yi; Li-Ping Shen; Xiang-Zhong Ye; Yang Zhang; Hui Wang; Hong Ke; Jing-Dong Song; Ke-Ping Hu; Bo-Lin Cheng; Feng Qiu; Peng-Cheng Yu; Wen-Ting Zhou; Ran Zhao; Lei Cao; Gao-Feng Dong; Sheng-Li Bi; Gui-Zhen Wu; George Fu Gao; Jerry Zheng
Journal:  Vaccine       Date:  2021-01-20       Impact factor: 3.641

6.  Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model.

Authors:  Rémi Vernet; Emily Charrier; Erika Cosset; Sabine Fièvre; Ugo Tomasello; Julien Grogg; Nicolas Mach
Journal:  Vaccines (Basel)       Date:  2021-05-10

7.  Multi-Epitope Vaccine Design Using an Immunoinformatic Approach for SARS-CoV-2.

Authors:  Ye Feng; Haiping Jiang; Min Qiu; Liang Liu; Shengmei Zou; Yun Li; Qianpeng Guo; Ning Han; Yingqiang Sun; Kui Wang; Lantian Lu; Xinlei Zhuang; Shanshan Zhang; Shuqing Chen; Fan Mo
Journal:  Pathogens       Date:  2021-06-11

8.  T cell epitopes of SARS-CoV-2 spike protein and conserved surface protein of Plasmodium malariae share sequence homology.

Authors:  Md Mehedi Hassan; Shirina Sharmin; Jinny Hong; Hoi-Seon Lee; Hyeon-Jin Kim; Seong-Tshool Hong
Journal:  Open Life Sci       Date:  2021-06-23       Impact factor: 0.938

Review 9.  Genomic Variability and Post-translational Protein Processing Enhance the Immune Evasion of Mycoplasma hyopneumoniae and Its Interaction With the Porcine Immune System.

Authors:  Gaojian Li; Enoch Obeng; Jinqi Shu; Jianhong Shu; Jian Chen; Yuehong Wu; Yulong He
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

10.  Lessons Learned from Cutting-Edge Immunoinformatics on Next-Generation COVID-19 Vaccine Research.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee
Journal:  Int J Pept Res Ther       Date:  2021-07-10       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.